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Heart-type Fatty Acid Binding Protein as an Adjunct to Cardiac 
Troponin-I for the Diagnosis of Myocardial Infarction
We hypothesized that when used in combination with cardiac troponins, heart-type fatty 
acid binding protein (H-FABP) would have greater diagnostic value than conventional 
markers for the early diagnosis of myocardial infarction (MI). Patients with typical chest 
pain at a single emergency department were consecutively enrolled. Initial blood samples 
were drawn for H-FABP, myoglobin, creatine kinase isoenzyme MB (CK-MB), and cardiac 
troponin-I (cTnI) measurements. MI was defined by serial cTnI measurements. To evaluate 
the adjunctive role of biochemical markers, we derived and compared logistic regression 
models predicting MI in terms of their discrimination (area under the receiver operating 
characteristics curve, AUC) and overall fit (Bayesian information criterion, BIC). Seventy-
six of 170 patients were diagnosed as having MI. The AUC of cTnI, H-FABP, myoglobin, 
and CK-MB were 0.863, 0.827, 0.784, and 0.772, respectively. A logistic regression model 
using cTnI (P = 0.001) and H-FABP (P < 0.001) had the biggest AUC (0.900) and the best 
fit determined by BIC. Sensitivity, specificity, positive likelihood ratio, and negative 
likelihood ratio of this model at 30% probability were 81.6%, 80.9%, 4.26, and 0.23, 
respectively. H-FABP has a better diagnostic value than both myoglobin and CK-MB as an 
adjunct to cTnI for the early diagnosis of MI.
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Biochemical markers, such as the highly sensitive and specific 
cardiac troponins, play a pivotal role in the diagnosis and man-
agement of patients with acute coronary syndrome (ACS) (1). 
With its higher sensitivity and virtually total specificity, cardiac 
troponin has become a critical determinant for the diagnosis of 
myocardial infarction (MI) (2). 
  Because cardiac troponins generally do not appear in the se-
rum prior to 4-10 hr after symptom onset, early markers such as 
myoglobin have been used (3). However, as the sensitivity of 
troponin assays continues to improve and as the 99th percen-
tile of the upper reference limit (URL) is used as a cutoff for the 
diagnosis of MI, the clinical value of such early markers is now 
doubtful (4-6).
  Heart-type fatty acid binding protein (H-FABP) is one of the 
most abundant proteins in the heart and has performed better 
than myoglobin for the early diagnosis of MI (7-9). Rapid point-
of-care tests (POCT) of H-FABP have also shown similar results 
(10, 11).
  We hypothesized that when used in combination with cardi-
ac troponins, H-FABP would have greater diagnostic value than 
other conventional markers for the early diagnosis of MI.
  The aim of this study was to test this hypothesis by compar-
ing the diagnostic performances of initial biochemical markers 
including H-FABP, myoglobin, and creatine kinase isoenzyme 
MB (CK-MB) along with cardiac troponin-I (cTnI).  
MATERIALS AND METHODS
Patients
We performed this study at a single academic, urban emergen-
cy department (ED) with an annual census of approximately 
65,000 from December 2006 to September 2007. Patients with 
chest pain who visited the ED between 9:00-17:00 on weekdays 
were screened upon the availability of a research nurse. 
  Patients were consecutively enrolled by senior residents or 
attending physicians of emergency medicine if their chest pain 
had satisfied any of the following criteria: 1) typically located in 
the substernal region, 2) sense of heaviness or squeezing nature, Kim KS, et al.  •  H-FABP as an Adjunct to cTnI for MI
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3) caused by exercise, or 4) relieved by resting or nitroglycerin. 
  Exclusion criteria included age under 18 yr old, refusal to 
participate, and history of chronic renal insufficiency. Patients 
with increased levels of serum creatinine (≥ 1.5 mg/dL [132 μM/
L]) were further excluded from the analysis to reduce false posi-
tive results, because elimination of H-FABP mostly depended 
on renal excretion (12). This study was approved by the institu-
tional review board, and all participants gave informed consent 
(IRB No. B-0706/046-011).
 
Measurement of biochemical markers
Immediately after enrollment, peripheral blood samples were 
collected for initial biochemical assays. cTnI, myoglobin, and 
CK-MB were measured at an emergency clinical laboratory us-
ing the Dimension
® clinical chemistry system (Siemens, New-
ark, NJ, USA) with a one-step enzyme immunoassay based on 
the “sandwich” principle. 
  H-FABP was measured by the research nurse using Cardio-
Detect
® med (Rennesens GmbH, Berlin, Germany) and Car-
dioDetect
® quant (Rennesens GmbH). After placing three drops 
of whole blood onto a test strip of CardioDetect
® med, H-FABP 
in the serum was bound to the monoclonal antibody resulting 
in a red line within 15 min. In order to avoid interpretation prob-
lems of qualitative measures of CardioDetect
® med, CardioDe-
tect
® quant was further used to quantify the results (13). The 
medical staff responsible for patient care was blinded to the re-
sults of the assay.
  The URLs and coefficients of variation (CV) of biochemical 
markers provided by the manufacturer at the specific limit were 
as follows: cTnI (99% URL = 0.07 ng/mL, CV = 15%), myoglobin 
(95% URL = 92 ng/mL, CV = 3.2%), CK-MB (95% URL = 3.6 ng/
mL, CV = 9.7%), and H-FABP (99% URL = 7 ng/mL, CV = 15%). 
 
Outcomes
All patients underwent serial electrocardiography (ECG) and 
serial cTn-I measurements. Other diagnostic evaluations that 
were at the discretion of the attending physicians, included multi-
detector row coronary angiographic computed tomography 
(MDCT), conventional coronary angiography (CAG), a tread-
mill test, or cardiac single photon emission computed tomog-
raphy (SPECT).
  Acute MI was defined as having a typical rise and fall in serial 
cTn-I with ischemic ECG changes or significant coronary lesions 
(2). ST segment elevation myocardial infarction (STEMI) was 
defined as having initial ECG changes indicative of a significant 
ST elevation (≥ 2 continuous leads of ≥ 0.1 mV in limb leads or  
≥ 0.2 mV in precordial leads) in MI patients. Non-ST segment 
elevation myocardial infarction (NSTEMI) was defined as hav-
ing any initial ECG findings other than a significant ST elevation 
in MI patients. Angina was diagnosed in the presence of signifi-
cant coronary lesions found on CAG or MDCT or with positive 
test results on the treadmill test or SPECT in the absence of ele-
vated cTn-I. Non-cardiac was diagnosed in the presence of neg-
ative results on CAG, MDCT, the treadmill test, or SPECT.
 
Statistical analyses
Continuous variables are expressed as means ± standard devia-
tion (SD), and categorical data are presented as the percent fre-
quency of occurrence. The Student t-test was used to compare 
continuous variables, and the chi-squared test was used to com-
pare binomial variables.
  The performances of initial biomarkers were compared us-
ing the area under the receiver operating characteristics curve 
(AUC).
  To assess an adjunctive role of biochemical markers, we de-
rived multivariate logistic regression models for the diagnosis 
of MI using variables composed of initial biochemical markers, 
i.e. Model 1 using cTnI only, Model 2 using cTnI and H-FABP, 
Model 3 using cTnI and myoglobin, and Model 4 using cTnI 
and CK-MB.
  Because AUC ignores the predicted probability values and 
the goodness-of-fit of the model, the performances of these 
models were compared in terms of discrimination and overall 
fit (14). Discrimination was assessed using AUC, and overall fit 
was assessed using Bayesian information criterion (BIC). When 
using maximum likelihood estimation, it is possible to increase 
the likelihood by adding variables. BIC is a criterion for model 
selection that penalizes the number of variables to avoid over-
fitting (15). Unlike a likelihood ratio (LR) test, BIC can be used 
to compare the fit of two models which are not nested. A model 
is better than another if it has a smaller BIC value (16).
  Since AUC weighs sensitivity and specificity equally, AUC can-
not precisely estimate the performance of predictive models 
under the conditions in which sensitivity is clinically more im-
portant. Therefore, the diagnostic performances of initial bio-
chemical markers at URL and of logistic regression models at 
30% probability were examined using sensitivity, specificity, pos-
itive LR, and negative LR with each 95% confidence intervals.
  All statistical procedures were performed using Stata version 
10.1 (Stata corp., College Station, TX, USA), and a two-tailed P 
value < 0.05 was considered as statistically significant.
 
RESULTS
A total of 186 patients were enrolled during the study period. 
After excluding 16 patients with elevated serum creatinine, 170 
patients were included in the final analysis. 
  Among 76 patients (44.7%) with MI, 54 had STEMI, and 22 
had NSTEMI. Among 94 patients (55.3%) with non-MI, 41 had 
angina, and 53 had non-cardiac chest pain. The clinical charac-
teristics of patients are described in Table 1.
  Receiver operating characteristics (ROC) curves of initial bio-Kim KS, et al.  •  H-FABP as an Adjunct to cTnI for MI
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chemical markers are presented in Fig. 1. AUCs of myoglobin 
and CK-MB were 0.784 (95% confidence intervals [CI], 0.711-
0.858) and 0.772 (95% CI, 0.697-0.847), respectively. Those were 
significantly lower than that of cTnI, which was 0.863 (95% CI, 
0.808-0.919). AUC of H-FABP was 0.827 (95% CI, 0.761-0.893).
  Logistic regression models using initial biochemical markers 
were derived and assessed in terms of discrimination and overall 
fit and are presented in Table 2. Only H-FABP had an indepen-
dent predictive value when combined with cTnI in the model. 
The logistic regression model including cTnI and H-FABP (Mod-
el 2) had the best discrimination ability measured by AUC. How-
ever, it was not statistically different from that of Model 1 (cTnI 
only). Model 2 also had the best overall fit measured by BIC (i.e., 
the smallest BIC). A difference in BIC over 20 means a very de-
cisive support for the selection of model with lower BIC (16).
  ROC curves of Model 1 and Model 2 were presented in Fig. 2.
  Sensitivity, specificity, positive LR, and negative LR of initial 
biochemical markers at URL and at the 30% predictive proba-
bility of logistic regression models are described in Table 3. In 
contrast to Model 2, neither Model 3 nor Model 4 had any im-
provement of diagnostic performances compared with Model 1 
in terms of sensitivity.  
DISCUSSION
In this study, only H-FABP had an adjunctive diagnostic value 
to initial cTnI for the diagnosis of MI. The discrimination power 
of cTnI was best among initial biochemical markers, and other 
Table 2. Performances of logistic regression models for diagnosis of MI
Variables   Model 1   Model 2   Model 3   Model 4
Variable 1
   OR (95% CI)*






    0.001
cTnI
127.0 (6.6-2436.9)
   0.001
cTnI
82.1 (2.4-2833.0)
   0.015
Variable 2
   OR (95% CI)*









   0.426
CK-MB
1.1 (0.8-1.4)
   0.506
Discrimination
   AUC (95% CI)





   0.121
0.871 (0.813-0.928)
   0.593
0.845 (0.783-0.908)
   0.237
Overall fit
   Log (likelihood)
   BIC










   4.486
-76.141
-71.206
   4.682
*OR per 1 unit increment of each biochemical marker; 
†When compared with AUC of Model 1; 
‡When compared with BIC of Model 1. MI, myocardial infarction; cTnI, cardiac 
troponin-I; H-FABP, heart-type fatty acid binding protein; CK-MB, creatine kinase isoenzyme MB; OR, odds ratio; CI, confidence intervals; AUC, area under the receiver operating 
characteristics curve; BIC, Bayesian information criteria.
Table 1. Clinical characteristics of patients
Parameters MI Non-MI P value
Patients, No. 76 94
Age (yr) (means ± SD) 60.0 ± 11.8 58.6 ± 15.6 0.491
Male Sex, No. (%) 53 (69.7%)   62 (66.0%) 0.600
Diabetes, No. (%) 14 (18.4%)   15 (16.0%) 0.671
Hypertension, No. (%) 34 (44.7%)   39 (41.5%) 0.671
Dyslipidemia, No. (%) 13 (17.1%)   25 (26.6%) 0.140
Ischemic heart disease, No. (%) 12 (15.8%)   19 (20.2%) 0.458
Current smoker, No. (%) 41 (54.0%)   35 (37.2%) 0.029
Symptom duration, No. (%)
   ≤ 3 hr
   3-6 hr
   > 6 hr





  43 (45.5%)
  14 (40.9%)
33 (9.1%)
  4 (4.5%)
-
Diagnostic evaluations, No. (%)
† 
   CAG
   MDCT
   Treadmill test






  40 (42.6%)
  40 (42.6%)
  13 (13.8%)
  6 (6.4%)
-
*Cases with missing data of symptom duration; 
†One can have more than one eva-
luation; 
‡Evaluations are not indicated in these cases. MI, myocardial infarction; No., 
number; SD, standard deviation; CAG, coronary angio  graphy; MDCT, multi-detector 




















Fig. 1. Receiver operating characteristics curves of initial biochemical markers for 
the diagnosis of myocardial infarction. cTnI indicates cardiac troponin-I; H-FABP, 
heart-type fatty acid binding protein; CK-MB, creatine kinase isoenzyme MB. *P value 
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markers other than H-FABP had a significantly lower AUC than 
that of cTnI. A logistic regression model including cTnI and H-
FABP had the highest AUC. The overall fit determined by BIC 
was best in the model that included both cTnI and H-FABP. 
Combining cTnI and H-FABP in the logistic regression model 
has resulted in increased sensitivity.
  Clinical decisions for the management of MI are guided by 
various clinical and laboratory findings such as demographics, 
history, ECG, physical examination, and biochemical markers. 
Early identification of MI may enable physicians to initiate ag-
gressive medical treatments or early invasive management, es-
pecially in patients with high risk (17). Myoglobin is considered 
useful in the early detection of MI because of its high sensitivity 
(17). However, our results suggest that H-FABP may play a great-
er role in the early detection of MI.
  There are several possible reasons why H-FABP may be su-
perior to myoglobin as an early adjunctive marker of MI. One 
possibility is that the levels of H-FABP in cardiac muscles are 2 
Table 3. Diagnostic performances of initial biochemical markers and logistic regression models for the diagnosis of MI*
Markers/Models Cutoff Sensitivity Specificity Positive LR Negative LR
cTnI 0.07 ng/mL 67.1 (55.3-77.2)   91.5 (83.4-96.0)   7.88 (3.99-15.58) 0.36 (0.26-0.50)
H-FABP      7 ng/mL 100 (94.0-100) 10.6 (5.5-19.1) 1.12 (1.04-1.20)                0 (NA)
H-FABP    10 ng/mL 85.5 (75.2-92.2)   62.8 (52.1-72.3) 2.30 (1.74-3.03) 0.23 (0.13-0.40)
Myoglobin    92 ng/mL 46.1 (34.7-57.8)   94.7 (87.5-98.0)   8.66 (3.57-21.02) 0.57 (0.46-0.70)
CK-MB   3.6 ng/mL 51.3 (39.7-62.8)   95.7 (88.8-98.6) 12.06 (4.51-32.25) 0.51 (0.40-0.64)
Model 1 0.3
† 67.1 (55.4-77.5)   89.4 (81.3-94.8)   6.31 (3.44-11.60) 0.37 (0.27-0.51)
Model 2 0.3
† 81.6 (71.0-89.5)   80.9 (71.4-88.2) 4.26 (2.77-6.54) 0.23 (0.14-0.37)
Model 3 0.3
† 68.4 (56.7-78.6)   89.4 (81.3-94.8)   6.43 (3.51-11.80) 0.35 (0.25-0.50)
Model 4 0.3
† 68.4 (56.7-78.6)   89.4 (81.3-94.8)   6.43 (3.51-11.80) 0.35 (0.25-0.50)
*Data are shown percentages or ratio with 95% confidence intervals; 
†Predicted probability of 0.3 was used for a cutoff. MI, myocardial infarction; LR, likelihood ratio; cTnI, 



















Fig. 2. Receiver operating characteristics curves of logistic regression model for the 
diagnosis of myocardial infarction. Model 1 was derived using cTnI only as a predictive 
variable and model 2 was derived using both cTnI and H-FABP. cTnI indicates cardiac 
troponin-I; H-FABP, heart-type fatty acid binding protein.
Model	1
Model	2
to 10 folds higher than the levels in skeletal muscle, while the 
levels of myoglobin in cardiac muscles are 2 folds lower than 
the levels in skeletal muscles. A second possibility is that nor-
mal baseline concentrations of H-FABP are considerably lower 
than myoglobin. These two facts suggest that H-FABP may have 
higher sensitivity and specificity for myocardial injury than myo-
globin. While H-FABP was superior to myoglobin in this study, 
the specificity of H-FABP at 7 ng/mL was only 10.6%. This low 
specifity is discordant with previous studies using CardioDetect
® 
med (10, 11, 18). One possible cause of this discrepancy is the 
use of a new definition of MI. Another is the high prevalence of 
MI or myocardial ischemia in this study. H-FABP is a very sen-
sitive marker, which can be elevated in patients with ischemia 
or even congestive heart failure (19). However, when a cutoff 
value of 10 ng/mL was used, H-FABP demonstrated improved 
specificity while retainning high sensitivity (Table 3).
  CK-MB is highly specific to myocardial injury. However, the 
initial CK-MB has low sensitivity because CK-MB takes a simi-
lar amount of time as cTnI to appear in serum. In fact, the use-
fulness of CK-MB resides mainly in the diagnosis of re-infarc-
tion because of its short half-life (1). 
  Unlike older studies using enzyme-linked immunosorbent 
assays (ELISA), rapid POCT of H-FABP was used in this study (7, 
8). Furthermore, CardioDetect
® quant has enabled quantitative 
measurements of this rapid POCT, eliminating the interpreta-
tion problem raised by Mad et al. (18). The whole assay time 
was less than 20 min. It is worth mentioning that rapid POCT  
of H-FABP was superior to conventional ELISA of myoglobin. 
Rapid POCT has several merits, especially in emergency situa-
tions. It would shorten the time lag for the diagnosis and does 
not require a specific laboratory facility. Quantitative tests have 
some advantages over qualitative tests, too. For instance, higher 
levels generally indicate a greater probability of myocardial in-
jury or a larger size of myocardial infarction. Thus, along with 
other biomarkers or clinical findings, quantitative measures of 
H-FABP can be used for diagnosis, risk stratification, and prog-
nosis of patients with MI (19, 20).
  Due to the outstanding diagnostic performance of cardiac Kim KS, et al.  •  H-FABP as an Adjunct to cTnI for MI
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troponins, H-FABP is likely to play a role only in the early pre-
sentation after symptom onset. That is the reason why we have 
only evaluated initial biomarkers. 
  Subgroup analyses performed in patients with different symp-
tom durations did not demonstrate any results worth mention-
ing. Furthermore, the relatively modest patient number has lim-
ited this kind of analysis.
  Several limitations apply to this study. First is that we did not 
exclude patients with STEMI. Because early biochemical mark-
ers are not helpful in these patients, it might have been better to 
have excluded these patients at the enrollment step. 
  Second is that the prevalence of MI was high (46.0%). This is 
probably due to the fact that we included patients with typical 
angina pain who require diagnostic evaluations to confirm di-
agnosis. Thus the results of this study might not reflect the usual 
population suspected of acute coronary syndrome. However, 
our patients are representative of the patients with a high risk 
and prevalence of MI. 
  In conclusion, the initial H-FABP measured by quantitative 
POCT has a better diagnostic value than initial myoglobin or 
initial CK-MB as an adjunct to the initial cardiac troponins for 
the early diagnosis of MI. H-FABP deserves further investiga-
tion for the early diagnosis of MI, especially in patients present-
ing early after symptom onset.
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H-FABP, myoglobin, creatine kinase isoenzyme MB (CK-MB), and cTnI were measured in consecutive patients with typical chest 
pain at a single emergency department. Seventy-six of 170 patients had MI. Area under the curve (AUC) of cTnI, H-FABP, 
myoglobin, and CK-MB were 0.863, 0.827, 0.784, and 0.772, respectively. A logistic regression model using cTnI (P = 0.001) and 
H-FABP (P < 0.001) had the biggest AUC (0.900) and the best fit. H-FABP has a better diagnostic value than both myoglobin and 
CK-MB as an adjunct to cTnI for the early diagnosis of MI.